Spotlight
Clinical
CME/CE
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
In this episode of Speaking of Urology®, Amar Kishan, MD, highlights findings from phase 3 MIRAGE trial (NCT04384770), which compared Magnetic Resonance Imaging-guided stereotactic body radiotherapy with Computed Tomography-guided stereotactic body radiotherapy in localized prostate cancer. Kishan is an associate professor of radiation oncology and urology and the chief of genitourinary oncology for radiation oncology at University of California, Los Angeles.
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Related Videos
Related Content
